NextCure Inc
NXTC4.920USD
+0.030+0.61%
Market hours （ET）Quotes delayed by 15 min
137.79MMarket Cap
LossP/E TTM
More Details of NextCure Inc Company
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.
Company Info
Ticker SymbolNXTC
Company nameNextCure Inc
IPO dateMay 09, 2019
CEOMr. Michael Richman
Number of employees43
Security typeOrdinary Share
Fiscal year-endMay 09
Address9000 Virginia Manor Rd Ste 200
CityBELTSVILLE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code20705-4214
Phone12403994900
Websitehttps://www.nextcure.com/
Ticker SymbolNXTC
IPO dateMay 09, 2019
CEOMr. Michael Richman
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Richman
Mr. Michael Richman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
34.69K
+2.46%
Dr. David S. Kabakoff, Ph.D.
Dr. David S. Kabakoff, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.19K
--
Dr. Udayan Guha, M.D., J.D.
Dr. Udayan Guha, M.D., J.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin G. Shaw, J.D.
Mr. Kevin G. Shaw, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Dr. Timothy Mayer, Ph.D.
Dr. Timothy Mayer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Sol Langermann, Ph.D.
Dr. Sol Langermann, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Sourav Kundu, Ph.D.
Dr. Sourav Kundu, Ph.D.
Senior Vice President - Development and Manufacturing
Senior Vice President - Development and Manufacturing
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Richman
Mr. Michael Richman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
34.69K
+2.46%
Dr. David S. Kabakoff, Ph.D.
Dr. David S. Kabakoff, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.19K
--
Dr. Udayan Guha, M.D., J.D.
Dr. Udayan Guha, M.D., J.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Aug 1
Updated: Fri, Aug 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sofinnova Investments, Inc
8.32%
Affinity Asset Advisors LLC
7.17%
Pfizer Inc
6.14%
Citi Investment Research (US)
4.42%
OrbiMed Advisors, LLC
3.55%
Other
70.40%
Shareholders
Shareholders
Proportion
Sofinnova Investments, Inc
8.32%
Affinity Asset Advisors LLC
7.17%
Pfizer Inc
6.14%
Citi Investment Research (US)
4.42%
OrbiMed Advisors, LLC
3.55%
Other
70.40%
Shareholder Types
Shareholders
Proportion
Hedge Fund
11.47%
Investment Advisor/Hedge Fund
9.20%
Venture Capital
8.38%
Corporation
6.14%
Investment Advisor
5.03%
Research Firm
4.42%
Private Equity
3.55%
Individual Investor
1.65%
Family Office
0.12%
Other
50.03%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
90
1.31M
49.02%
-419.80K
2025Q1
93
15.91M
56.72%
-4.70M
2024Q4
99
16.68M
59.57%
-2.91M
2024Q3
113
18.48M
66.07%
-4.88M
2024Q2
115
18.65M
66.68%
-4.54M
2024Q1
124
18.78M
67.32%
-1.96M
2023Q4
131
15.99M
57.34%
-5.33M
2023Q3
145
15.65M
56.21%
-6.81M
2023Q2
152
15.96M
57.33%
-6.41M
2023Q1
194
15.85M
57.06%
-8.98M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sofinnova Investments, Inc
2.67M
9.53%
--
--
Mar 31, 2025
Affinity Asset Advisors LLC
2.30M
8.21%
--
--
Mar 31, 2025
Pfizer Inc
1.97M
7.03%
+79.00K
+4.18%
Apr 23, 2025
Citi Investment Research (US)
1.42M
5.06%
+30.33K
+2.18%
Mar 31, 2025
OrbiMed Advisors, LLC
1.14M
4.07%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
987.32K
3.52%
--
--
Mar 31, 2025
Cable Car Capital LLC
670.10K
2.39%
+54.22K
+8.80%
Mar 31, 2025
Acadian Asset Management LLC
488.44K
1.74%
--
--
Mar 31, 2025
Renaissance Technologies LLC
479.96K
1.71%
-39.34K
-7.58%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
465.54K
1.66%
-1.10K
-0.24%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
